Blog

Marketwide benchmarking and pharma brand benchmarking provide two key perspectives on how a rare disease treatment performs.

Cell and gene therapies in development today provide real world evidence analytics for how rare diseases will be treated tomorrow.

Competing Humira biosimilars are already on the market. Examining them provides pharma market insights such as specialty pharmacy trends and a go-to-market strategy.

Specialty pharmacy data from patient journey orchestration and specialty pharmacy analytics helps specialty pharmacies outperform competitors.

Rare disease patient data is generated from a wide range of sources. We examine specialty pharmacy data and rare disease registries.

The very name “rare disease” implies that the average person should expect to meet someone with a rare disease infrequently, if ever. Each individual rare disease in fact affects only a small portion of the human population. Taken together, rare diseases as a whole affect millions of people worldwide. Those who have a rare disease

As work on genetics has advanced, so has the creation of biologics and biosimilars. Today, biosimilars are more common, changing the specialty drug landscape.

Tracking the right specialty pharma KPIs matters. Here’s what to consider and how to implement digital tracking tools.

Patient Services plays a key integrative role both before and after product launch, and along with Hub tools can better integrate patient care.

The FDA’s recent approval of Roctavian marks the first approved gene therapy for adults with severe hemophilia A.